Blinatumomab

Therapeutic indications

Blinatumomab is indicated for:

B-precursor acute lymphoblastic leukaemia (ALL), Philadelphia chromosome negative, CD19 positive

Population group: only adolescents (12 years - 18 years old) , adults (18 - 65 years old)

Blinatumomab is indicated as monotherapy for the treatment of adults with Philadelphia chromosome negative CD19 positive relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL).

Blinatumomab is indicated as monotherapy for the treatment of adults with Philadelphia chromosome negative CD19 positive B-precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.

Blinatumomab is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B-precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

B-precursor acute lymphoblastic leukaemia (ALL), Philadelphia chromosome negative, CD19 positive

Population group: only children (1 year - 12 years old)

Blinatumomab is indicated as monotherapy for the treatment of adults with Philadelphia chromosome negative CD19 positive relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL).

Blinatumomab is indicated as monotherapy for the treatment of adults with Philadelphia chromosome negative CD19 positive B-precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.

Blinatumomab is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B-precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Blinatumomab is contraindicated in the following cases:

Lactation

Lactation

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.